Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tapestry, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tapestry, Inc. trades at $115.23 (market cap $22.87B). The key difference: Tapestry, Inc. is far larger — about 3× Spyre Therapeutics Inc. Common Stock's market cap, and Tapestry, Inc. pays a 1.61% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tapestry, Inc. for 70 Days on average.
| SYRE | TPR | |
|---|---|---|
Market Cap | $7.52B | $22.87B |
Volume | 1,441,031 | 1,963,570 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $164.78 |
52-Week Low | $22.18 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $6.52B | $25.67B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TPR trades at $115.03, down 1.87% today, with a neutral technical signal and bearish moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined to $183M. Recent earnings beats and a $174.64 consensus price target suggest upside potential. International growth in China and Europe supports fiscal 2027 expansion plans.
Outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and 52% upside to price target. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.85 P/E. Strong cash flow generation and Coach brand momentum provide fundamental support despite recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
